文献速递胸部肿瘤

突变EGFR肽段与HLA I类分子结合与NSCLC生存改善相关

HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival.
PubMed 文献 · J Thorac Oncol · 2020-09-11

该研究利用NETMHCpan 4.0预测能结合并呈递突变EGFR衍生肽段的保护性HLA I类等位基因,并在TCGA肺腺癌患者中分析其与临床结局的关联。结果显示,携带保护性等位基因的患者无病生存和总生存均显著改善,且效应独立于EGFR突变类型、分期、年龄和性别。

要点

  • 预测并体外验证了针对EGFR p.L858R和p.E746_A750del的保护性HLA I类等位基因。
  • 携带保护性等位基因的肺腺癌患者无病生存和总生存更优。
  • 突变EGFR特异性免疫在部分早期肺癌患者中可能存在并预示更好预后。

核心结论

  • 携带保护性HLA I类等位基因的EGFR突变阳性肺腺癌患者临床结局改善。

研究设计与样本

  • 利用NETMHCpan 4.0按预设标准预测结合突变EGFR肽段的HLA I类等位基因,并在TCGA肺腺癌患者中关联临床结局。
  • 体外验证肽-HLA等位基因结合的预测结果。

主要发现

  • 鉴定出12个HLA I类等位基因符合针对EGFR p.L858R的保护性标准,6个符合针对EGFR p.E746_A750del的保护性标准。
  • TCGA中36例携带EGFR p.L858R或p.E746_A750del的肺腺癌患者中,12例(三分之一)至少携带一个保护性等位基因。
  • 携带保护性等位基因的患者无病生存更好(风险比:0.20,95%CI:0.05-0.78)。
  • 携带保护性等位基因的患者总生存更好(风险比:0.13,95%CI:0.02-0.64)。
  • 保护效应独立于EGFR突变类型、分期、年龄和性别。

临床怎么用

  • HLA I类等位基因分型可能有助于识别EGFR突变肺腺癌中预后较好的患者亚群。
  • 突变EGFR特异性免疫的存在提示部分早期肺癌患者可能从免疫相关机制中获益。

局限性

  • 研究基于TCGA数据,样本量有限,尤其携带保护性等位基因的患者数较少。
  • 保护性等位基因基于预设标准的in silico预测,虽经体外验证,但临床关联需进一步前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cancer-associated mutations have the potential to generate neoantigens and elicit CD8-positive T-cell-dependent adaptive immune responses. There are currently no reports of CD8-positive T-cells with specificity for neoepitopes generated by EGFR mutations, which are driver oncogenes in a subset of patients with lung cancer. METHODS: We used NETMHCpan 4.0 to identify putative protective human leukocyte antigen (HLA) class I allotypes that are predicted in silico to bind and present mutant EGFR-generated peptides on the basis of predefined criteria. We associated the presence or absence of these alleles with clinical outcomes in patients from The Cancer Genome Atlas with lung adenocarcinoma. RESULTS: We identified 12 HLA class I alleles that fulfilled the predefined criteria for being protective for EGFR p.L858R and six for EGFR p.E746_A750del, the two most common EGFR mutations in lung cancer. We validated the in silico predictions for peptide-HLA allele binding in vitro. A third (12 of 36) of patients with mostly early stage lung adenocarcinoma in The Cancer Genome Atlas with either EGFR p.L858R or EGFR p.E746_A750del had at least one protective allele in their host genomes. More importantly, patients with protective alleles exhibited better disease-free (hazard ratio: 0.20, 95% confidence interval: 0.05-0.78) and overall survival (hazard ratio: 0.13, 95% confidence interval: 0.02-0.64), and this effect was independent of the EGFR mutation type, stage, age, and sex. CONCLUSIONS: Our data revealed that clinical outcomes were improved in patients with EGFR mutation-positive lung adenocarcinoma who harbored protective HLA class I alleles. Thus, immunity with specificity for mutant EGFR is possible in a subset of patients with early stage lung cancer and portends a better prognosis.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dimou A, Grewe P, Sidney J, et al. HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival. J Thorac Oncol. 2020. PMID: 32927123. doi:10.1016/j.jtho.2020.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。